ReportWire

Tag: Healthcare

  • Microbes can create a more peaceful world: Scientists call to action

    Microbes can create a more peaceful world: Scientists call to action

    [ad_1]

    Newswise — Microorganisms should be ‘weaponised’ to stave off conflicts across the globe, according to a team of eminent microbiologists. 

    The paper ‘Weaponising microbes for peace’ by Anand et al, outlines the ways in which microbes and microbial technologies can be used to tackle global and local challenges that could otherwise lead to conflict, but warns that these resources have been severely underexploited to date. 

    Professor Kenneth Timmis, Founding Editor of AMI journals Environmental Microbiology, Environmental Microbiology Reports and Microbial Biotechnology, says that worldwide deficits and asymmetries in basic resources and services considered to be human rights, such as drinking water, sanitation, healthy nutrition, access to basic healthcare and a clean environment, can lead to competition between peoples for limited resources, tensions, and in some cases conflicts. 

    “There is an urgent need to reduce such deficits, to level up, and to assure provision of basic resources for all peoples. This will also remove some of the causes of conflicts. There is a wide range of powerful microbial technologies that can provide or contribute to this provision of such resources and services, but deployment of such technologies is seriously underexploited,” Professor Timmis said. 

    The paper then lists a series of ways in which microbial technologies can contribute to challenges such as food supply and security, sanitation and hygiene, healthcare, pollution, energy and heating, and mass migrations and overcrowding. For example, microbes are at the core of efforts to tackle pollution by bioremediation, replacing chemical methods of treating drinking water with metalloid conversion systems, and producing biofuels from wastes. 

    “There is now a desperate need for a determined effort by all relevant actors to widely deploy appropriate microbial technologies to reduce key deficits and asymmetries, particularly among the most vulnerable populations,” Professor Timmis said..  

    “Not only will this contribute to the improvement of humanitarian conditions and levelling up, and thereby to a reduction in tensions that may lead to conflicts, but also advance progress towards attainment of Sustainable Development Goals,” he said. . 

    “In this paper, we draw attention to the wide range of powerful microbial technologies that can be deployed for this purpose and how sustainability can be addressed at the same time. We must weaponise microbes for peace.”

    RECOMMENDED ACTIONS TO IMPLEMENT RELEVANT MICROBIAL TECHNOLOGY SOLUTIONS TO DEFICITS 

    We need to urgently supply to communities lacking adequate levels of basic resources/services the infrastructure and know-how (capacity building), and funding for 

    1. use of agrobiologics to increase crop yields, by providing green nitrogen, stimulating plant growth, and combatting pathogens and pests, 

    2. exploitation of plant:microbe partnerships to improve soil health and implement regenerative agriculture, 

    3. creation of nutritious fermented food from locally available crops, 

    4. better use of microbes in the feed and food supply chains, 

    5. production of microbial food for humans and farm animals, 

    6. drinking water production and quality safeguarding, 

    7. waste treatment with resource recovery, 

    8. creation of modular DIY digital medical centres, 

    9. production of vaccines and medicines, 

    10. bioremediation and biorestoration of the environment in general and natural ecosystems in particular, to create healthier habitats and promote biodiversity 

    11. reduction of greenhouse gas production and capturing carbon, 

    12. production of biofuels, 

    13. creation of local employment opportunities associated with the above, 

    14. development of transdisciplinary approaches, using chemistry-related, computation technologies, psychology-related and other approaches that are synergistic to microbial solutions and 

    15. education in societally relevant microbiology 

    ‘Weaponising microbes for peace’ is published in Microbial Biotechnology, an Applied Microbiology International publication, on March 7 2023. 

    The authors are Shailly Anand, John E. Hallsworth, James Timmis, Willy Verstraete, Arturo Casadevall, Juan Luis Ramos, Utkarsh Sood, Roshan Kumar, Princy Hira, Charu Dogra Rawat, Abhilash Kumar, Sukanya Lal, Rup Lal, Kenneth Timmis. 

    To read the full paper, click HERE. 

    To find out more about AMI, visit https://appliedmicrobiology.org/ or https://www.the-microbiologist.com/. 

    [ad_2]

    Applied Microbiology International

    Source link

  • Mayo Clinic reconhecida mais uma vez como “Melhor Hospital do Mundo” na classificação da Newsweek

    Mayo Clinic reconhecida mais uma vez como “Melhor Hospital do Mundo” na classificação da Newsweek

    [ad_1]

    Newswise — ROCHESTER, Minnesota — A Mayo Clinic em Rochester foi classificada mais uma vez como nº 1 do mundo pela Newsweek na lista dos “Melhores Hospitais do Mundo”. A classificação é uma homenagem ao trabalho da equipe da Mayo Clinic. 

    “Entre as célebres marcas de grandes hospitais… não há apenas atendimento de primeira classe, pesquisa de ponta e inovação de última geração. As melhores instituições também têm em comum outra qualidade: consistência,” declara a Newsweek. “Os melhores hospitais do mundo atraem consistentemente os melhores profissionais e oferecem os melhores resultados para os pacientes, além de importantes novas terapias e pesquisas. De todos os hospitais no mundo, poucos são aqueles que conseguem fazer tudo isso anos após ano. Os melhores pertencem a um clube muito exclusivo.” 

    A classificação da Newsweek é baseada em resultados de pesquisa com pacientes, em recomendações de hospitais pelos pares reunidas por meio de uma pesquisa internacional com mais de 80.000 profissionais da saúde e nas principais métricas de desempenho, como segurança do paciente, medidas de higiene, qualidade do atendimento e resultados relatados pelos pacientes. A Newsweek anunciou a classificação em 1 de março. 

    ### 

    Sobre a Mayo Clinic  
    A Mayo Clinic é uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinic para obter outras notícias da Mayo Clinic. 

    [ad_2]

    Mayo Clinic

    Source link

  • Why Medical Practices Must Embrace Digital Marketing | Entrepreneur

    Why Medical Practices Must Embrace Digital Marketing | Entrepreneur

    [ad_1]

    Opinions expressed by Entrepreneur contributors are their own.

    There was a time when medical practitioners didn’t need to market themselves. New patients would choose doctors or other medical professionals based on location, availability, and most commonly, referrals. But unless you live in a small town, there’s a good chance this is no longer the case.

    Healthcare customers are more empowered than ever before. They have access to digital channels, which can be used in innumerable ways to decide how and where they will receive their healthcare. And if you’re not yet utilizing these digital channels, you’re undoubtedly missing out.

    Related: How to Improve Your Practice Management and Deliver a Better Patient Experience

    It’s a funnel, not a waiting room

    Medical practitioners often focus on the waiting room to indicate their success. If all the seats are full, that must mean your business is doing just fine, right? Sure — but what about the long term?

    The danger in using booked appointments as an indicator of successful marketing is that you lose sight of the bulk of the customer journey. If you can’t answer the question, “How did my customer end up in my waiting room?” you won’t be able to replicate that level of success in the future. You may enjoy a surge of initial bookings or annual visits, but if nothing fills up the rest of the funnel, those will eventually dry up.

    Today, the rest of the funnel is digital. Thanks to the internet, healthcare customers are more comfortable than ever researching their ailments before even consulting a practitioner. By the time a patient arrives at your doorstep, they have already spent significant time assessing their options. Your job is to ensure that their path always leads back to you. If you aren’t leveraging digital platforms, you’re missing out.

    Become a source of information

    With prospective patients using the internet to search for information about their conditions more now than ever before, it’s essential to become the source of that information. For medical practices and practitioners, content has now become the most valuable form of marketing you can include in your strategy.

    Patients are choosing practitioners based on the level of their perceived knowledge, so by creating content that answers their questions and gives them the information they’re seeking, you will instantly increase your credibility. If prospective patients feel you have the knowledge they seek, there is a far better chance they’ll book an appointment with you.

    Your prospects will seek out information on various channels, including social media and Google searches — so you need to ensure that your practice utilizes each of these channels.

    Your focus should depend on your company’s needs. If you’re just starting out, you’ll want to focus on ranking in search engine results. That entails optimizing your content, website and social media pages for search engine optimization (SEO). Once you’ve achieved that, you can start to spread your focus onto other digital channels.

    Related: Here’s How Healthcare Companies Have Embraced Digitalization

    Know your audience

    Marketing strategies in the healthcare sector need to be structured around the audience. Not all specialties are the same — and neither are the patients seeking treatment. Your marketing efforts and strategies should reflect that.

    A chiropractor, for instance, might limit the reach of their marketing efforts to about a 30-mile radius, as it’s unlikely their customers are going to travel for this type of care. A specialist cardiologist, on the other hand, may well see customers traveling to their practice from across the country, so their marketing reach should be far wider.

    Understanding the makeup of your customers from a geographical perspective will help you craft a digital and social media strategy that ensures you get in front of the prospective patients who will most likely make appointments with you.

    The landscape of healthcare has irrevocably changed. The balance of power through knowledge has shifted, and prospective patients are capable of gaining a wealth of information before they even step foot inside your practice. This very change needs to be leveraged by the healthcare industry to ensure that the funnel of patients continues to be filled, credibility is established through knowledge sharing, and providers are meeting patients at each touchpoint in their digital journey to the waiting room.

    [ad_2]

    Sergio Alvarez

    Source link

  • Hospitals Face Challenges When Implementing Enhanced Recovery Programs for Surgery

    Hospitals Face Challenges When Implementing Enhanced Recovery Programs for Surgery

    [ad_1]

    Key takeaways

    • Striving to improve patient care: Enhanced recovery programs (ERPs) provide hospitals with patient-centered protocols and standards to improve the safety and quality of care for patients undergoing surgery.
    • Understanding barriers to compliance: Although previous studies have shown substantial improvements when hospitals implement ERPs, some hospitals have reported difficulties successfully implementing these programs.
    • ERPs are not always easily implemented: This study found that out of 151 hospitals that implemented an ERP for colorectal surgery, most of them (85%) had difficulty improving compliance with a national protocol.

    Newswise — CHICAGO: Enhanced recovery programs (ERPs) provide hospitals with the highest-quality resources to improve patient care for surgery, but many hospitals still struggle to successfully implement these programs and may need more structured resources to boost compliance rates, according to findings published in the Journal of the American College of Surgeons (JACS). 

    “Enhanced recovery programs have been instrumental in promoting evidence-based, standardized perioperative care that focuses on engaging patients from the moment it’s decided they will have surgery, all the way to their transition back into the community,” said Elizabeth Wick, MD, FACS, a professor of surgery at the University of California, San Francisco (UCSF) and a study co-author. “While some previous studies have reported substantial improvements when hospitals implement these programs, the goal of this study was to take a deep dive into process compliance and understand how successful these hospitals were at implementing enhanced recovery programs.”

    The research stems from the Improving Surgical Care and Recovery Collaborative (ISCR), a partnership between the American College of Surgeons (ACS), the Agency for Healthcare Research and Quality, and the Johns Hopkins Medicine Armstrong Institute for Patient Safety and Quality. That collaboration began in 2016 with the goal of helping hospitals implement ERPs, also known as enhanced recovery after surgery, around the country by providing them with centralized support and tools for standardizing patient care — from guidelines on infection control to optimal nutrition. The program ran until 2022 and assisted about 300 hospitals in initiating and spreading ERPs across multiple surgical specialties, according to Dr. Wick.

    “Another principle we try to emphasize through the program is the importance of multidisciplinary or collaborative surgical care with surgeons, anesthesiologists, hospitals, and nurses,” Dr. Wick explained. “All members of the team need to come together to provide the best surgical care for patients and their families.”

    For this study, researchers analyzed data from 151 hospitals enrolled in an ISCR protocol for colorectal surgery to determine if they got better or worse at complying with ERP process measures — and by how much — over an 18-month period. Participating hospitals, which were located throughout the country but were mostly teaching hospitals in urban areas, entered data on process measure compliance and 30-day patient outcomes into a customized registry through the ACS National Surgical Quality Improvement Program® (ACS NSQIP®).

    The researchers looked at six common components of an ERP protocol for colorectal surgery:

    • Oral antibiotics: Did the patient receive oral antibiotics within 24 hours of the operation?
    • Mechanical bowel preparation: Did the patient complete a mechanical bowel preparation (oral medication used to cleanse the large bowel of fecal matter) before the operation?
    • Multimodal pain control: Did the patient use scheduled, nonopioid pain medication in addition to, or in place of, opioid pain medication within 24 hours of the operation?
    • Early mobilization: Was the patient mobile (able to walk and stand) within 24 hours of the operation?
    • Early liquid intake: Did the patient receive liquid within 24 hours of the operation?
    • Early solid intake: Did the patient receive solid food within 48 hours of the operation?

    Looking at changes in process measure compliance from the start of the program to the end, the team divided compliance rate changes into three categories: worsening (<0%), minimal improvement (0-20% change in compliance), and substantial improvement (greater than 20% change in compliance).

    Researchers looked at each of the six process measures separately as an individual opportunity for improvement and looked at a composite measure of all six process measures by the hospital.

    Key findings

    • Out of 151 hospitals studied, only 15% of the hospitals achieved substantial improvements in compliance across the entire protocol.
    • The researchers identified 663 individual opportunities available for improvement; of these opportunities, substantial improvement in compliance only occurred 20% of the time.
    • Process measures that involved simple interventions, such as pain control or oral antibiotics, improved the most by 23% and 16%, respectively. In contrast, early mobilization improved the least, by 2%.
    • On average, the individual components of the ERP were implemented for patients less than 70% of the time across all the hospitals.

    The research focused on a national ERP for colorectal surgery, but the authors note that the results may be generalizable across many surgical specialties.

    “I think these findings suggest that there’s a significant opportunity available to improve compliance with enhanced recovery programs, and in turn, improve patient outcomes, because prior studies have shown that high compliance leads to better outcomes,” said Tejen Shah, MD, a general surgery resident at Ohio State University Wexner Medical Center and lead author of the study.

    Addressing barriers

    Though the study only included data from hospitals that participated in the ISCR collaborative, which could cause selection bias, the trends reflected in the study paint a larger picture of barriers to implementing ERPs, the researchers said. When implementing ERPs, inadequate resources or limited leadership support may hinder progress, for example, or there may be ineffective collaboration and communication among team members.

    In their journal article, the researchers identified the ACS Quality Verification Program™ (ACS QVP) as one program that may offer hospitals a more structured approach to achieving quality improvement measures. The ACS QVP provides hospitals with customized, actionable recommendations on improving surgical quality, such as leadership and safety culture, based on the framework of 12 evidence-based standards vetted by the ACS. The program may help hospitals and providers break down each component of the ERP into manageable items, the researchers noted.

    “The overall structure of the ACS QVP may also be advantageous to hospitals. It really helps surgeons engage with hospital leadership at a very high level,” Dr. Wick said.

    “Lower compliance rates didn’t occur because of a lack of effort. People were passionate about trying to implement the enhanced recovery program. But it was challenging,” she added. “I think this study highlights the fact that we need to collectively figure out how to address those barriers and make this work easier. We have the opportunity to improve prioritization and access to resources, whether it’s project management or expertise in data skills, and then ultimately hold people accountable for doing the work.”

    “This research confirms what we as surgeons know — the work of improvement is challenging. It takes tremendous focus and determination,” Dr. Wick said. “The good news is that the ACS has exceptional expertise in how to improve surgical quality. With more than 17 surgical quality programs, the ACS is a valuable resource for every hospital’s quality journey.”

    Study coauthors are Leandra Knapp, MS; Mark E. Cohen, PhD; Stacy A. Brethauer, MD, MBA, FACS; and Clifford Y. Ko MD, MS, MSHS, FACS. All authors are affiliated with the Division of Research and Optimal Patient Care, the American College of Surgeons, Ohio State University Wexner Medical Center, the University of California, San Francisco (UCSF), or the University of California, Los Angeles (UCLA).

    The study authors have no relevant disclosures to report. This research was supported by funding from the Agency for Healthcare Research and Quality (AHRQ). Ms. Knapp is supported by funding from the U.S. Department of Health and Human Services and is employed by the American College of Surgeons, subcontracted under Johns Hopkins Medicine Armstrong Institute for Patient Safety and Quality for Improving Surgical Care and Recovery contract with the AHRQ. Dr. Wick is supported by funding from the National Institutes of Health.

    This research was also presented at the Southern Surgical Association 134th Annual Meeting in Palm Beach, Florida, December 2022. This study is published as an article in press on the JACS website.

    Citation: Shah T, Knapp L, Cohen M, et al. Truth of Colorectal Enhanced Recovery Programs: Process Measure Compliance in 151 Hospitals. Journal of American College of Surgeons. DOI: 10.1097/XCS.0000000000000562.

    # # #

    About the American College of Surgeons 

    The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 84,000 members and is the largest organization of surgeons in the world. “FACS” designates a surgeon is a Fellow of the American College of Surgeons.  

    The Journal of the American College of Surgeons (JACS) is the official scientific journal of ACS. Each month, JACS publishes peer-reviewed original contributions on all aspects of surgery, with the goal of providing its readership the highest quality rapid retrieval of information relevant to surgeons.

    [ad_2]

    American College of Surgeons (ACS)

    Source link

  • Keck Medicine of USC names Ikenna (Ike) Mmeje president and CEO of USC Arcadia Hospital

    Keck Medicine of USC names Ikenna (Ike) Mmeje president and CEO of USC Arcadia Hospital

    [ad_1]

    Newswise — LOS ANGELES — Keck Medicine of USC has named Ikenna (Ike) Mmeje president and CEO of USC Arcadia Hospital (USC-AH), effective March 13.

    In this position, Mmeje will further the health system’s mission to expand access to specialized health care and research to the San Gabriel Valley and beyond. He will oversee all management and operations of the hospital, including corporate compliance, strategic plan implementation and fundraising.

    “Mmeje will utilize his wealth of knowledge and experience running complex, high-performing hospitals in his new role leading USC Arcadia Hospital,” said Rod Hanners, CEO of Keck Medicine.

    Mmeje replaces current USC-AH president and CEO Dan Ausman, who is retiring after a long and successful career in health care, including 12 years with USC-AH.

    “I am humbled and excited to join USC Arcadia Hospital,” said Mmeje. “The hospital has a rich 120-year history of caring for patients and the community, and I look forward to advancing its legacy and mission far into the future.”

    Prior to joining Keck Medicine, Mmeje served as chief operating officer (COO) of both MemorialCare Long Beach Medical Center and Miller Children’s & Women’s Hospital Long Beach. Previously, he held CEO and COO roles with Tenet Healthcare.

    Mmeje is active on a number of boards, committees and organizations, including the American College of Healthcare Executives and the National Association of Health Services Executives, and is a Fellow of the American College of Healthcare Executives.  

    He holds a Bachelor of Arts in public health and social welfare from the University of California, Berkeley and a Master of Health Services Administration from the University of Michigan.

    USC-AH, founded in 1903, affiliated with Keck Medicine in July 2022. It is a full-service community hospital offering advanced cardiovascular services. Los Angeles County has designated the hospital as both a heart attack receiving center and a comprehensive stroke center, as well as an Emergency Department Approved for Pediatrics. The hospital also offers a variety of surgical services in orthopaedics, neurosurgery, obstetrics, gynecology, and cancer care, plus physical rehabilitation and many other medical specialties. 

    ###

    For more information about Keck Medicine of USC, please visit news.KeckMedicine.org.

    [ad_2]

    Keck Medicine of USC

    Source link

  • Silicon Valley Confronts the End of Growth. It’s a New Era for Tech Stocks.

    Silicon Valley Confronts the End of Growth. It’s a New Era for Tech Stocks.

    [ad_1]

    Silicon Valley could use a reboot. The biggest players aren’t growing, and more than a few are seeing sharp revenue declines. Regulators seem opposed to every proposed merger, while legislators push for new rules to crack down on the internet giants. The Justice Department just can’t stop filing antitrust suits against Google. The initial public offering market is closed. Venture-capital investments are plunging, along with valuations of prepublic companies. Maybe they should try turning the whole thing on and off.

    The only strategy that seems to be working is to lay people off. Tech CEOs suddenly are channeling Marie Kondo, tidying up and keeping only the people and projects that “spark joy,” or at least support decent operating margins. Layoffs.fyi reports that tech companies have laid off more than 122,000 people already this year.

    [ad_2]

    Source link

  • خبير من مايو كلينك للرعاية الصحية: الذكاء الاصطناعي يحسن دقة تنظير القولون

    خبير من مايو كلينك للرعاية الصحية: الذكاء الاصطناعي يحسن دقة تنظير القولون

    [ad_1]

    Newswise — لندن – يقضي جيمس إيست، دكتور الطب، أيامه في فحص قولون الناس بمهارة، والبحث عن السلائل المشبوهة التي قد تتحول يومًا ما إلى سرطان، والتخلص منها. يقول طبيب الجهاز الهضمي في مايو كلينك للرعاية الصحية في لندن، إن القدرة على التعرف على مخاطر الإصابة بالسرطان والقضاء عليها في الحال خلال تنظير القولون من الأمور المجزية للغاية في مهنته التي اختارها. 

    يظل تنظير القولون المعيار الذهبي في الكشف عن سرطان القولون والمستقيم والوقاية منه. لكن هذا الإجراء له حدود. تشير بعض الدراسات إلى أن أكثر من نصف حالات سرطان القولون بعد تنظير القولون تعود لآفات لم يتم اكتشافها خلال تنظير القولون السابق للمريض. 

    حاليًا يقوم الباحثون في مايو كلينك بدراسة كيفية تسخير الذكاء الاصطناعي لزيادة معدل اكتشاف السلائل. في الواقع، يستخدم أطباء الجهاز الهضمي الذكاء الاصطناعي كأداة لتحسين الرعاية في مجموعة واسعة من الحالات، بهدف إيجاد مؤشرات المرض الخفية في وقت مبكر عندما تكون الأمراض أكثر قابلية للعلاج. 

    بالنسبة لسرطان القولون، فإن نظام الذكاء الاصطناعي يعمل إلى جانب الطبيب في الوقت الفعلي، ويقوم بمسح فيديو تنظير القولون المباشر ورسم مربعات حمراء صغيرة حول السلائل التي قد يتم إغفالها لولاه.  

    يقول الدكتور إيست: “جميعنا نعرف خاصية التعرف على الوجه. فبدلًا من تدريب الذكاء الاصطناعي على التعرف على الوجوه، فإننا ندربه على التعرف على السلائل”. 

    يمكن إضافة الذكاء الاصطناعي إلى تنظير القولون التقليدي للتعرف على السلائل التي قد يتم إغفالها لولاه.  

    سرطان القولون هو ثاني أخطر أنواع السرطان في العالم. شهدت العقود القليلة الماضية ارتفاعًا مطردًا في معدلات الإصابة بسرطان القولون والمستقيم بين الشباب. بالرغم من أن تنظير القولون قد يكون أداة فحص فعّالة، فإن الدكتور إيست يقول إنه ثمة تباينٌ في قدرة أخصائيي التنظير الداخلي على اكتشاف السلائل محتملة التسرطن. 

    وللمفارقة، فإن اكتشاف السلائل هو الأصعب لدى المرضى الذين هم في أمس الحاجة إلى الفحص. إن المرضى بأمراض الأمعاء الالتهابية، مثل: داء كرون أو التهاب القولون التقرحي يكونون عرضة بشكل كبير لخطر الإصابة بسرطان القولون والمستقيم. لكن الآفات في مرحلة ما قبل التسرطن التي تصيبهم يغلب عليها الشكل المسطح أو تكون بارزة قليلًا فقط، على عكس السلائل التي تكون على شكل فُطر بصلي الشكل لدى غير المصابين بأمراض التهاب الأمعاء. 

    تقول نايانتارا كويلهو-برابهو، بكالوريوس الطب والجراحة، طبيب الجهاز الهضمي في مايو كلينك في مدينة روتشستر بولاية مينيسوتا: “يخضع معظم من يصابون بهذه السرطانات لتنظير القولون بانتظام، ومع ذلك يتم إغفال الآفات لأن الأورام تكون دقيقة للغاية”. 

    تعتقد الدكتورة كويلو-برابهو أنه يمكن تدريب الذكاء الاصطناعي على تعقب السلائل المخادعة التي تبدو غير ضارة.  

    وتضيف: “إن مايو كلينك مهيأة دون غيرها لإجراء هذا النوع من الأبحاث. فنحن نجري تنظيرات قولون للمتابعة على 800 إلى 900 مريض بأمراض الأمعاء الالتهابية سنويًا. ونتيجة لذلك، قمنا بتجميع بنك بيانات ضخم يمكننا استخدامه لتطوير أنظمة الذكاء الاصطناعي اللازمة لتحسين طريقة إجرائنا لتنظير القولون لهؤلاء المرضى”. 

    يوفر بنك البيانات هذا ما تسميه الدكتورة كويلو برابهو وخبراء آخرون “الحقيقة على أرض الواقع”، والملاحظات والقياسات الواقعية المستخدمة لتدريب واختبار خوارزميات الذكاء الاصطناعي. وحاليًا يقوم فريقها بتدوين بيانات مجموعة فرعية مكونة من 1000 مريض، عبر مشاهدة فيديوهات تنظير القولون الواحد تلو الآخر، ووضع علامات على الآفات في كل إطار، ومن كل زاوية. وبعد وضع علامات توضيحية على الصور، فسيقوم الباحثون بإرسالها إلى جهاز كمبيوتر لتوليد نوع من خوارزميات “التعلم الآلي” تعمل بالذكاء الاصطناعي وتمكن الآلة من تعلم كيفية التعرف على السلائل لدى المصابين بأمراض التهاب الأمعاء على وجه الخصوص من تلقاء نفسها. 

    تقوم الدكتورة كويلو برابهو، طبيب الجهاز الهضمي، وكادمان ليجيت، دكتور الطب، وزملاؤهما بإنشاء منصة رقمية جديدة للتنظير الداخلي هي الأولى من نوعها تقوم بتصوير جميع الإجراءات الجراحية داخل مايو، وربطها بالسجلات الطبية، ثم دمج الذكاء الاصطناعي مرة أخرى في الإجراءات كلما أمكن ذلك.  

    وتقول: “بمجرد أن نطور الخوارزميات، فإنه يمكننا تشغيلها على فيديوهات الإجراءات التي نقوم بها لاختبار أدائها”.  

    لمزيد من المعلومات، تفضل بزيارة ديسكافريز إيدج.  

    ###  

    نبذة عن مايو كلينك للرعاية الصحية 

    مايو كلينك للرعاية الصحية، الموجودة في لندن، هي شركة فرعية مملوكة بالكامل لـ مايو كلينك، وهي مركز طبي أكاديمي غير هادف للربح. تُصنَّف مايو كلينك في الولايات المتحدة في المرتبة الأولى في تخصصات كثيرة أكثر من أي مستشفى آخر وفقًا لتقرير يو إس نيوز آند وورد ريبورت بسبب: جودة الرعاية. مايو كلينك للرعاية الصحية هي المدخل في المملكة المتحدة لتلك التجربة التي لا مثيل لها. تفضل بزيارة مايو كلينك للرعاية الصحية لمزيد من المعلومات. 

    نبذة عن مايو كلينك 

    مايو كلينك منظمة غير ربحية تلتزم بالابتكار في الممارسات السريرية والتعليم والبحث وتوفير الرعاية والخبرة لكل من يحتاج إلى التعافي والرد على استفساراته. لمعرفة المزيد من أخبار مايو كلينك، تفضَّل بزيارة شبكة مايو كلينك الإخبارية. 

    [ad_2]

    Mayo Clinic

    Source link

  • First-of-its-Kind Study Examines the Impact of Cannabis Use on Surgical Patients’ Post-Procedure Healthcare Needs

    First-of-its-Kind Study Examines the Impact of Cannabis Use on Surgical Patients’ Post-Procedure Healthcare Needs

    [ad_1]

    BYLINE: Jacqueline Mitchell

    Newswise — BOSTON – As legislation in multiple states eases former restrictions around medical and recreational cannabis in the United States, an increasing proportion of the population reports use of the drug. Between 2016 and 2018, more than 22 percent of Massachusetts residents reported any prior cannabis use for medical or recreational reasons. However, little is known about cannabis use in patients who undergo surgery or interventional procedures, where cannabis use has important additional clinical implications.

    In a new study published in The Lancet’s eClinical Medicine, researchers led by anesthesiologists at Beth Israel Deaconess Medical Center (BIDMC) analyzed de-identified data from patients who underwent non-cardiac surgery in Boston between 2008 and 2020. The scientists found that cannabis users had a higher complexity of co-existing conditions overall, including mood disorders such as depression and substance use disorders. Patients with a diagnosed cannabis use disorder more often required advanced postprocedural healthcare – such as admission to an intensive care unit – compared to non-users. However, patients whose use of cannabis was not classified as a disorder had lower odds of requiring advanced healthcare after surgery compared to patients who never use cannabis.

    “Our analysis revealed that cannabis use is very common and has substantially increased among patients undergoing surgery, reflecting trends in the general population; however, differential effects on postprocedural health care utilization were observed between patients with moderate non-medical cannabis use and patients with a cannabis use disorder,” said corresponding author Maximillian S. Schaefer, Director of the Center for Anesthesia Research Excellence at BIDMC. “We hope our data helps make clinicians aware of how different patterns of cannabis use might represent different patient populations, which in turn translates into distinct perioperative risk profiles.”

    In this hospital registry study, Schaefer and colleagues analyzed de-identified data from 210,639 adult patients undergoing noncardiac surgery at BIDMC between January 2008 and June 2020. Non-medical cannabis use was identified before procedures during routine, structured interviews about past and ongoing habits of drug use, in accordance with the American Society of PeriAnesthesia Nursing recommendations. Patients with cannabis use disorder were identified through diagnostic codes.

    Over the entire study period, the researchers found that more than 16,000 patients, or 7.7 percent, used cannabis prior to surgery, of which 14,045 (87 percent) were identified as non-medical users and 2,166 (13 percent) had a diagnosis of cannabis use disorder. Of all the patients undergoing surgery, a total of 24,516 patients, or 12 percent, required advanced post-procedural healthcare utilization, among which 1,465 patients self-identified as non-medical cannabis users, 418 patients presented with cannabis use disorder and 22,633 patients had no reported ongoing cannabis use.

    Overall, patients who self-identified as cannabis users were on average younger, more often male, and more likely to suffer from depression, anxiety and schizoaffective disorders. Substance use disorders related to alcohol, cocaine, IV drugs, prescription medications and psychedelic drugs were more frequent in patients who used cannabis.

    “As these comorbidities have been associated with increased complications including arrhythmias and sudden cardiac death after anesthesia, a history of cannabis use disorder might serve as an indicator of potentially complicating factor for patients undergoing anesthesia that in turn contribute to the requirement of higher-level healthcare utilization after surgery,” Schaefer said.

    Compared to patients who did not use cannabis, patients with a diagnosis of cannabis use disorder had higher odds of requiring advanced post procedural healthcare utilization. Specifically, a diagnosis of cannabis use disorder was linked with higher odds of a 30-day hospital readmission, compared to patients who did not use cannabis.

    By contrast, patients with reported ongoing non-medical cannabis use had lower odds of advanced post-procedural healthcare unit utilization compared to patients who did not use cannabis. Moreover, such use was linked to shorter hospital length of stay than patients who did not use cannabis. Over the course of the study period, the scientists saw the prevalence of cannabis use rise from 5 percent in 2008 to 14 percent by 2020 and observed higher rates of cannabis use among those undergoing surgery than previous studies reported. While the scientists acknowledge the discrepancy could be the result of regional consumption patterns, they suggest their inclusion of ongoing self-reported non-medical cannabis users based on structured pre-admission interviews paints a more accurate picture than findings that identified patients’ cannabis use on diagnostic codes alone.

    “This cohort represents a distinctively different patient population of more general non-medical users,” said Schaefer. “These differential findings in patients who self-identified as ongoing, non-medical cannabis users without a diagnosis of disorder strongly suggest that future studies need to differentiate these two patient populations. Findings based on the identification of cannabis use from diagnostic codes alone might not be applicable to most mainstream cannabis users.”

    Co-authors included first author Elena Ahrens, Luca J. Wachtendorf, Laetitia S. Chiarella, Sarah Ashrafian, Aiman Suleiman, Tim M. Tartler, Basit A. Azizi, Guangqing Chen, Amnon A. Berge, Denys Shay, Valerie Banner-Goodspeed, Haobo Ma, and Kevin P. Hill, of BIDMC; Bijan Teja, of University of Toronto; and Matthias Eikermann of Albert Einstein College of Medicine.

    This work was supported by an unrestricted, philanthropic grant of Jeff and Judy Buzen. Hill has served as a consultant for Greenwich Biosciences and has received an honorarium from Walters-Klewer as an author. Schaefer received funding for investigator-initiated studies from Merck and Co which do not pertain to this manuscript. Schaefer received honoraria for presentations from Fisher and Paykel healthcare and Mindray medical information international limited period. All other authors declare no competing interests.

     

    [ad_2]

    Beth Israel Deaconess Medical Center

    Source link

  • NOTICE TO THE MEDIA: MP Fragiskatos to announce investment in health care research

    NOTICE TO THE MEDIA: MP Fragiskatos to announce investment in health care research

    [ad_1]

    Newswise — February 24 – London, Ontario – Peter Fragiskatos, Member of Parliament for London North Centre, will announce an investment that will support the work of research teams across the country to improve health care for Canadians. MP Fragiskatos will be joined by Dr. Bryan Neff, Vice-President (Research), Western University; Dr. Roy Butler, President and CEO, St. Joseph’s Health Care London;  and funding recipients from Western University and Lawson Health Research Institute.

    A media availability will follow the announcement.

    Date:   Monday, February 27, 2023

    Time: 10:00 a.m. (EST)

    Location:

    Western Centre for Public Health and Family Medicine, 1st floor atrium

    Western University

    1465 Richmond Street

    London, ON  N6G 2M1

     

    [ad_2]

    Canadian Institutes of Health Research (CIHR)

    Source link

  • The Medical Minute: Don’t wait to treat your enlarged prostate

    The Medical Minute: Don’t wait to treat your enlarged prostate

    [ad_1]

    Newswise — Half of all men develop enlarged prostates — also called benign prostatic hyperplasia — by the time they’re 50 years old. The walnut-sized gland never stops slowly growing. But like the fabled frog in hot water, men often don’t realize how disruptive the symptoms of an enlarged prostate have become.

    Benign prostatic hyperplasia is, like the name says, not malignant. It is not cancer. Instead, it’s the enlargement of the prostate caused by testosterone. “Because most men produce the hormone throughout their lives, the prostate continues to grow — typically inward, compressing the base of the bladder as well as the urethra,” said Dr. Jaime Herrera Caceres, a urologic oncologist at Penn State Health Specialty Services.

    Disruptive symptoms and possible complications

    An enlarged prostate makes the bladder work harder to push the urine out due to the increasingly narrow urethra. “Patients start not being able to empty their bladder completely,” Herrera Caceres said. “So maybe they’re retaining three to five ounces in their bladder, meaning it fills more quickly and they have to go more often.”

    Not only will those with an enlarged prostate typically have to wake up at night — often multiple times — to relieve themselves, they may also have a weaker urine stream and have to strain to urinate. “Going to the bathroom becomes stressful,” Herrera Caceres said. “When you’re out and about, you’re always conscious of where the next toilet is because you know you’ll need it soon.”

    Men may just accept the disruptive symptoms of their enlarged prostate and not seek treatment. But Herrera Caceres cautions that as the prostate continues to grow, serious complications can develop. “If you ignore the symptoms, you run the risk of bladder failure and kidney failure — of having a catheter or needing dialysis.”

    Diagnosis and treatment

    When patients see Herrera Caceres, he asks about their symptoms and how severe they are. He also measures urine flow to learn how weak or strong it is and examines the prostate to determine its size and shape to help guide him in finding the appropriate treatment.

    Prescription medications are the most common treatment for mild to moderate benign prostatic hyperplasia. Some relax the bladder neck muscles and muscle fibers in the prostate, making urination easier, Herrera Caceres explains. Others can shrink the prostate by decreasing the amount of the active form of testosterone, though these might take up to six months to be effective and may also reduce sexual desire.

    Having benign prostatic hyperplasia in itself does not cause erectile dysfunction, but some treatments might.

    Can you take Viagra if you have an enlarged prostate? Herrera Caceres says he has no concerns. In fact, for some patients he’s prescribed a different type of medication for erectile disfunction — Cialis — to control their enlarged prostate symptoms.

    For those with moderate to severe benign prostatic hyperplasia, or those who don’t respond to medication, surgery may be advised. “The classic option is a transurethral resection of the prostate,” Herrera Caceres said, explaining that it involves a surgeon going in with a heated loop into the prostatic urethra — the portion of the urethra that goes through the prostate — “and scraping from the inside. Basically, we’re digging a hole and opening the prostate so there’s a better flow.”

    Other surgical procedures include using heated water or vaper to burn the prostate from inside to open it and using a laser to enucleate the gland. These treatments require hospitalization for a day and a catheter for up to five days, Herrera Caceres said. “They may also cause retrograde ejaculation, in which the seminal vesicles fail to squish the semen into the prostate and instead it goes into the bladder.” 

    New outpatient treatment

    One new treatment option that Herrera Caceres calls “a game changer” is the minimally invasive procedure iTind. It involves placing a temporary stent in the prostatic urethra and having it slowly expand over the course of a week.

    “Patients are asleep for the 15-minute procedure and don’t need a catheter at all,” Herrera Caceres said. There’s also no hospital stay. Patients will return a week later to have the stent removed.

    The technology is new, with patients only tracked for three years thus far, Herrera Caceres says. Those results show continued relief from the symptoms of an enlarged prostate. Patients have reported mild to moderate discomfort during the week that the iTind device is in place, but once it’s removed, they don’t experience the side effects caused by the medications and other procedures used to treat, the urologist says.

    No matter what surgical procedure is used to treat the condition, as long as the body produces testosterone, the prostate will grow. “It may take eight or 10 years, but when it happens, patients should discuss their symptoms with their doctor to see if they should be treated with medication or another surgical procedure,” Herrera Caceres said.

    Related content:

    The Medical Minute is a weekly health news feature produced by Penn State Health. Articles feature the expertise of faculty, physicians and staff, and are designed to offer timely, relevant health information of interest to a broad audience.

    [ad_2]

    Penn State Health

    Source link

  • Cancer: In Italy every year over 8000 patients candidate for liquid biopsy

    Cancer: In Italy every year over 8000 patients candidate for liquid biopsy

    [ad_1]

    Newswise — Rome, 21 February 2023 – Almost 8,000 lung cancer patients are thought to qualify for a liquid biopsy each year in Italy in order to determine the best course of treatment. But in the not-too-distant future, the number of cancer patients for whom a simple blood test will choose the optimum course of treatment will grow dramatically. Blood sample enables continuous, real-time monitoring of the neoplasm’s development, much like in a video. An image of the tumour at the time of diagnosis can only be captured by a conventional biopsy, which is performed on tumour tissue. Also, even if it doesn’t currently reflect clinical practise, the difficulty is in using a blood test to make an early cancer diagnosis. The study, which is presented in the book “Liquid Biopsy: New Challenges in the Age of Immunotherapy and Precision Oncology,” by Antonio Russo, Ettore Capoluongo, Antonio Galvano, and Antonio Giordano, Ed. Elsevier, brings up truly innovative views on the use of liquid biopsy, which was presented today at a press conference in the Chamber of Deputies and has signatures from the top international experts.

    “Twenty years ago, in 2003, there were fewer than 50 publications in oncology that used the term “liquid biopsy,” but today there are more than 10,000, making it a real “hot topic,” states to Antonio Russo, COMU President, Full Professor of Medical Oncology at DICHIRONS – University of Palermo, and Treasurer of AIOM (Italian Association of Medical Oncology). The “Liquid Biopsy” manual serves as evidence of both the prominence of Sicily, specifically the University of Palermo, and the brilliance attained in this subject by Italian scholars across the globe.

    “Up to this point,“ continues Professor Russo, “the applications of liquid biopsy that have been shown effective in clinical practise involve advanced stage non-small cell lung cancer, for the assessment of the EGFR gene mutational status. In two clinical contexts, the method is suggested in these instances as a possible alternative for tumour tissue examination. 

    First of all, in patients who have just received a diagnosis and prior to beginning any kind of treatment, when the quantity or quality of tissue available is insufficient to perform the anticipated molecular analyses, when the molecular analysis of tissue has been found to be insufficient, or when it is impossible to obtain biopsy tissue due to the patient’s poor clinical conditions. It should be kept in mind that, even when used for histological diagnosis, the tissue sample is not acceptable for molecular characterization in roughly 30% of instances. In the second scenario, the liquid biopsy provides a very important contribution during the monitoring of patients with EGFR gene mutation, in progression after first-line treatment with targeted therapies, i.e. with first and second generation EGFR inhibitors. In these cases, blood sampling is very useful for searching for a specific resistance mutation and directing the change of cure, i.e. treatment with the third generation EGFR inhibitor. The latter, in light of the robust overall survival data, has now become a solid option on the front line and, given the high inhibitory activity, has made the use of liquid biopsy for the search for the resistance mutation secondary”.

    “The liquid biopsy has undoubted advantages over the traditional approach consisting of the analysis of tumor tissue – says Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine of Temple University in Philadelphia (USA) and Professor of Anatomy and Pathological Histology at the University of Sien, and Founder and President of the Sbarro Health Research Organization (SHRO). “It is minimally invasive, low-cost, has very fast reporting times and is practically free of complications, because it can be performed with a simple blood sample. Furthermore, it is characterized by a high level of acceptance by patients and can be repeated without problems, by performing serial sampling to highlight the onset of resistance to therapy in real time and, if necessary, modify the treatment.”

    “The liquid biopsy has undeniable advantages over the conventional method that involves the study of tumour tissue,” says Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine of Temple University in Philadelphia (USA) and Professor of Anatomy and Pathological Histology at the University of Siena, “It is less invasive, inexpensive, has extremely quick turnaround times, and is essentially complication-free because it can be carried out with a simple blood sample. Furthermore, serial sampling is used to highlight the development of therapy resistance in real time and, if necessary, change the treatment. It is characterised by a high level of patient acceptability and can be repeated without issues.

    Instead, very few patients opt to have a second tissue evaluation, in part because the general clinical circumstances often exclude it. Moreover, the tissue biopsy sample, particularly when it is obtained through fine-needle aspiration, may not necessarily be an accurate representation of the entire tumour. This is not the case with the liquid biopsy, which solves the issue of the heterogeneity of the tumour tissues by analysing the tumour DNA discharged into the circulation.”

    The predominant biopsy method currently utilised in clinical practise today is the examination of circulating tumour DNA, or ctDNA (circulating tumour DNA), which is a fraction of circulating free DNA (cell free DNA, or cfDNA), isolated from peripheral blood (particularly from plasma).

    “The chance of success is dependent on the quantity of ctDNA in the peripheral blood, which may impact the test’s sensitivity,” underlines Ettore Capoluongo, Full Professor of Clinical Biochemistry and Clinical Molecular Biology and SOC Director of Clinical Pathology and Genomics, Cannizzaro Hospital of Catania, “One drawback is that, depending on the volume and locations of the disease, the amount of ctDNA in the context of cfDNA is frequently limited, and this might result in “false negative” results on the liquid biopsy sample. The size and stage of the tumour are really connected to the concentration of ctDNA in plasma, with advanced-stage neoplasms releasing more ctDNA than early-stage ones. Exosomes, platelets, circulating tumour cells, circulating tumour RNA and microRNA, as well as other biological fluids like urine, saliva, ascitic fluid, and pleural could all be used in clinical practise in the future to provide additional information beyond that provided by the analysis of ctDNA isolated from plasma.” It is crucial that the measurement of these molecular tumour markers be as consistent as possible; for this reason, using liquid biopsy as part of the diagnostic process is the perfect scenario for clinic and laboratory collaboration.

    “Due to its capability to swiftly translate laboratory discoveries into clinical applications, the liquid biopsy must only be examined in laboratories that pass quality controls and serves as a key illustration of translational medicine,” explains Marcello Ciaccio, Full Professor of Clinical Biochemistry , Dean of the School of Medicine and Surgery of the University of Palermo, Past President and President-elect of SIBioC (Italian Society of Clinical Biochemistry and Clinical Molecular Biology), “which enables the simultaneous identification of all forms of genetic changes in several genes during a single liquid biopsy study. NGS is more cost-effective than a single gene method, according to cost analyses. This advantage becomes even clearer once a threshold of patients has been evaluated in order to fully realise the potential of NGS technologies, which enable the simultaneous profiling of several individuals while optimising costs and turnaround times. The subsequent step will be to make NGS approaches accessible and convenient to utilise. Building a real network is important to accomplish this goal.”

    “The liquid biopsy definitively establishes the importance of multidisciplinarity,” says Saverio Cinieri, National President of AIOM (Italian Association of Medical Oncology), “The Molecular Tumor Boards, interdisciplinary committees where various talents are combined to govern the clinical and decision-making processes of appropriateness, are responsible for selecting the material to be exposed to molecular analysis. Yet it’s important to make a distinction between regular clinical practise and research. Although if research efforts are in the right direction, it is not yet possible to diagnose cancer from a blood sample. Nowadays, the liquid biopsy plays a significant role as a predictor of response to therapy in lung cancer. An investigation based on a novel strategy, namely the methylation signatures of circulating free DNA, was presented at the most recent Congress of the European Society of Oncology. There were more than 6,000 participants who were over 50, appeared healthy, and had never been given a cancer diagnosis. In 1.4% of the participants, the test revealed changes in the methylation profile, which are common to more than 50 distinct forms of neoplasms. Among these individuals, the oncological diagnosis was confirmed in around 40% of the instances. Yet, in more than 60% of cases, no oncological illness diagnosis was made after the positive test results.”

    “The sensitivity of the liquid biopsy, in a context of early diagnosis, is therefore still conditioned by a high rate of false positives, the causes of which are being studied,” continues the AIOM President, “The emerging clinical applications of this procedure mainly concern colorectal, breast and advanced melanoma cancers. Indeed, there is solid and reproducible information regarding the characterization of RAS and BRAF genes for colorectal, PIK3CA for breast, BRAF and NRAS in melanoma. It is likely that plasma analysis for this type of alteration will soon be recommended in clinical practice”.

    “In order to personalise treatment, a very active area of study is the use of liquid biopsy in immunotherapy. This field has the potential to produce “dynamic” and reproducible biomarkers in the near future,” highlights Antonio Galvano, Associate Professor of Medical Oncology at the University of Palermo, “Only a fraction of patients today show a significant response or long-term benefit with immunotherapy drugs. Individual biological and immune factors affect the heterogeneity in the response. For this reason, the identification of predictive biomarkers of response or resistance to treatment, for example, with immune checkpoint inhibitors, assumes an important role. Numerous studies are underway with the aim of evaluating the potential use of cfDNA, ctDNA and soluble forms of immune checkpoints as predictive biomarkers of response. In recent years, our research group has published studies conducted mainly on lung, pancreatic and melanoma tumors in important international scientific journals. It is crucial to keep moving in this direction. “.

    “One of the roles of Patients’ Associations is to support the scientific community with regard to research progress, adopting a rigorous, but informative and easy to understand method,” continues Adriana Bonifacino, President of the IncontraDonna Foundation, “It is essential that patients are increasingly involved in trials, including those on liquid biopsy. The quality of life is becoming a central element in the evaluation of the innovativeness of treatments and the liquid biopsy fits into this context. Being able to monitor the evolution of the tumor in real time with a simple blood sample also represents an element of reassurance from a psychological point of view for the patient, as well as avoiding the invasiveness of traditional procedures on tumor tissue”.

    “The “Liquid Biopsy” book is distinguished by the special focus on educational aspects and by the inclusion of the so-called “expert comments,” authored by internationally known experts,”  concludes Professor Russo, “Our group of researchers from the University of Palermo has been conducting experiments on liquid biopsy since the early 2000s and is at the forefront in this sector, today with further studies on exosomes and on the determination of circulating immunocheckpoints. The exciting data from studies may also lead to changes in the parameters used to classify cancer stages. To the TNM system, where T describes the extent of the disease, N the status of the lymph nodes and M the possible presence of metastases, the B, such as blood, should be added, which provides information on circulating tumor DNA.”

     

     

    About the Sbarro Health Research Organization

    The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

    [ad_2]

    Sbarro Health Research Organization (SHRO)

    Source link

  • Walmart, Home Depot, Meta, DocuSign, Medtronic, and More Stock Market Movers

    Walmart, Home Depot, Meta, DocuSign, Medtronic, and More Stock Market Movers

    [ad_1]

    This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

    https://www.barrons.com/articles/stock-market-movers-5b0c54ae

    • Order Reprints
    • Print Article

    [ad_2]

    Source link

  • Five Faculty Selected for Newly Created “Rising Professorship”

    Five Faculty Selected for Newly Created “Rising Professorship”

    [ad_1]

    Newswise — Five from the Johns Hopkins School of Nursing (JHSON) have been selected as the inaugural holders of the newly established Term Professorship for Rising Faculty (Rising Professorship). The five faculty include Kamila Alexander, Teresa Brockie, Yvonne Commodore-Mensah, Laura Samuel, and Janiece Taylor.

    The Rising Professorship is a three-year period of funding for emerging and distinguished faculty to grow their research, increase their local, national, or global collaboration, strengthen their policy involvement, and advance their leadership within nursing and beyond.

    “We are delighted to announce this opportunity and to select these exceptional faculty,” says JHSON Dean Sarah Szanton, PhD, RN, FAAN. “This significant investment in faculty underscores our commitment to offering rising stars a place where they can both succeed in their careers and build the science, research, and networks needed to further nursing and improve health.”

    Kamila Alexander, PhD, MSN/MPH, RN, uses health equity and social justice lenses to examine the complex roles that intimate partner violence, HIV resilience, societal gender expectations, and economic opportunity play in the experience of intimate human relationships. Alexander is inaugural chair of the Nursing Initiative of the Mid-Atlantic Center for AIDS Research (CFAR) Consortium, lead faculty for the Violence Working Group at the Johns Hopkins Center for Injury Research and Policy, chair of the HIV/STI Committee of the Society for Adolescent Health and Medicine, and the associate director of the NIH-sponsored Interdisciplinary Research and Training in Trauma and Violence T32 Training Program at Johns Hopkins.

    Teresa Brockie, PhD, MSN, RN, FAAN, focuses on achieving health equity through community-based prevention and intervention of suicide, trauma, and adverse childhood experiences among vulnerable populations. Brockie is a member of the White Clay (A’aninin) Nation from Fort Belknap, Montana and leader of the Young Medicine Movement (YMM), which introduces Native youth to health science careers and provides mentorship by Indigenous researchers and clinicians to Fort Belknap scholars. Her intervention called Little Holy One aims to instill traditional Dakoda and Nakoda cultural values in children as a protective factor against adolescent suicide and substance use.

    Yvonne Commodore-Mensah, PhD, MHS, RN, FAHA, FPCNA, FAAN, seeks to reduce the burden of cardiovascular disease risk among Africans in the United States and in sub-Saharan Africa through community-engaged research and implementation science. She is a cardiovascular nurse epidemiologist and co-founder and president of the Ghanaian-Diaspora Nursing Alliance, a non-profit organization which advances nursing education in Ghana. Commodore-Mensah is principal investigator of the LINKED-BP and LINKED-HEARTS programs, two trials aimed to improve hypertension control and management of chronic conditions in community health centers.

    Laura Samuel, PhD, MSN, RN, FAAN, addresses socioeconomic disparities by advancing health equity for individuals and families with low incomes. Her current research examines the pathways that link low income and financial strain to physiologic aging. This includes investigating the health impact of policies and programs related to economic well-being for low-income households. Samuel’s research also looks at aspects of neighborhood and household environments that may influence health disparities. Her research interests stem from her clinical experience as a family nurse practitioner where she regularly witnessed the myriad of ways that a lack of financial resources can be detrimental to health.

    Janiece Taylor, PhD, MSN, RN, FAAN, identifies and addresses pain disparities with older women from underrepresented racial ethnic groups and helps individuals with disabilities increase social participation and independence. Taylor is principal investigator of a study that addresses unmet needs of caregivers aging with and into disabilities. She is co-associate director of JHSON’s RESILIENCE Center and principal faculty of its Center for Equity in Aging. Throughout her career, Taylor has received funding from the John A. Hartford Foundation, National Institute of Nursing Research, Mayday Foundation, the Robert Wood Johnson Foundation, Henry M. Jackson Foundation, and the Harold Amos Medical Faculty Program.

    “These faculty are already making tremendous impact. We can’t wait to see what they accomplish next.”

    ***

    Located in Baltimore, the Johns Hopkins School of Nursing is a globally-recognized leader in nursing education, research, and practice. In U.S. News & World Report rankings, the school is No. 1 nationally for its master’s and DNP programs. In addition, JHSON is ranked as the No. 3 nursing school in the world by QS World University and No. 1 for total NIH funding among schools of nursing for fiscal year 2020. The school is a four-time recipient of the INSIGHT Into Diversity Health Professions Higher Education Excellence in Diversity (HEED) Award and a three-time Best School for Men in Nursing award recipient. For more information, visit www.nursing.jhu.edu.

    [ad_2]

    Johns Hopkins School of Nursing

    Source link

  • ISPOR Publishes New Guidance on Designing and Conducting Patient Preference Studies

    ISPOR Publishes New Guidance on Designing and Conducting Patient Preference Studies

    [ad_1]

    Newswise — Lawrenceville, NJ, USA—February 13, 2023—Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Good Practices Report advancing recommendations to assist researchers and other stakeholders in designing, conducting, and disseminating patient-preference studies. It introduces the ISPOR Roadmap for Patient Preferences in Decision Making, which illustrates 5 important areas where patient-preference researchers should work with stakeholders. The report, “A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force,” was published in the February 2023 issue of Value in Health.

    “Patient preference studies are important because they promote patient centricity by engaging directly with real patients to inform the tradeoffs they are willing to make with treatment risks versus benefits. Patient preferences are also important to understand how patients value nonhealth outcomes. At the population level, patient preference research informs healthcare value assessments, resource allocation, public health programs, and shared decision making” said the report’s lead author John F. P. Bridges, PhD, Department of Biomedical Informatics at The Ohio State University in Columbus, OH, USA. “Our goal was to make these studies more helpful for decision makers such as health technology assessors, government regulators, and payers.”  

    The ISPOR Roadmap highlights how that usefulness and impact will be maximized when patient-preference researchers work with decision makers, patients and patient groups, and other stakeholders across 5 key areas: (1) Context; (2) Purpose; (3) Population; (4) Method; and (5) Impact. The ISPOR Roadmap is methods agnostic and will aid researchers and improve studies regardless of the preference method used.   

    Although the authors conceptualize the construct as a roadmap, they do not intend to suggest that it must be followed linearly. Rather, these are 5 broad considerations that can help those conducting preference research to enhance the likelihood of impacting decision making and being able to identify the impacts (both intended and unintended) that their studies have made.

    The report also includes a set of key questions that can guide researchers who are conducting patient-preference studies and support the critical appraisal of studies across each of the 5 elements. These questions help guide researchers and other stakeholders (eg, funders, reviewers, readers, etc) as they assess efforts that promote the ongoing impact of a particular preference study and additional studies in the future.

    “ISPOR has long been a leader in the creation of consensus-based methodological good practice guidance to study patient preference,” noted Bridges. “In fact, the 3 previously published reports are among the most used and widely cited Good Practices Reports that ISPOR has ever produced and published. The ISPOR Roadmap is designed to add to that earlier work and to enhance the policy relevance of patient-preference studies by providing guidance for including the decision makers’ perspective in study design as well as tools to critically appraise patient-preference studies based on their relevance to decisions.”

    This report was accompanied by an editorial from Julia F. Slejko, PhD and Susan dosReis, PhD, Department of Practices, Sciences, and Health Outcomes Research at the University of Maryland School of Pharmacy, Baltimore, MD, USA. Their commentary, “Navigating Patient-Preferences Studies for Cross-Stakeholder Decision Making: A Roadmap Guides the Way,” also published in the February 2023 issue of Value in Health, provides important background and context for those interested in the history of patient preference studies.

    “This Good Practices Report adds an important tool in the current landscape of preferences research,” said Slejko and dosReis. “It provides guidance for the successful development of patient-preference studies by enhancing transparency and communication around study design and goals. We agree with the authors’ comment that growth in patient-preferences studies will continue. Therefore, the right time for the ISPOR Roadmap is now. Its impact will be assessed over time as it is implemented by the research community.”
     

    ###

     

    ABOUT ISPOR
    ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
    Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  
     

    ABOUT VALUE IN HEALTH
    Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2021 impact factor score is 5.156 and its 5-year impact factor score is 6.779. Value in Health is ranked 9th of 88 journals in health policy and services, 18th of 109 journals in healthcare sciences and services, and 50th of 381 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
    Website  | Twitter (@isporjournals)


    ABOUT ISPOR GOOD PRACTICES REPORTS
    ISPOR has earned an international reputation for research excellence based, in part, on its Good Practices Reports. These highly cited reports are expert consensus recommendations on good practice standards for outcomes research (clinical, economic, and patient-reported outcomes) and on the use of this research in healthcare decision making. ISPOR Task Forces comprise subject matter experts representing different stakeholders from diverse work environments (ie, regulators, payers, manufacturers, technology assessors, etc from research, government, academic, and industry sectors around the world). All ISPOR Good Practices Reports are published in the Society’s scientific journal, Value in Health, and are made freely available as part of the Society’s mission. The Society’s Good Practices Reports have been recognized with an ASAE “Power of A” award that acknowledges innovative, effective, and broad-reaching programs that have a positive impact on the world.

    [ad_2]

    ISPOR–The Professional Society for Health Economics and Outcomes Research

    Source link

  • Remote symptom reporting systems for patients may reduce outpatient waiting lists

    Remote symptom reporting systems for patients may reduce outpatient waiting lists

    [ad_1]

    Newswise — Digital systems for patients to monitor and report symptoms remotely may offer a solution to reduce outpatient waiting lists, according to a new review published by the Journal of the Royal Society of Medicine.

    The review, led by researchers from the Centre for Patient Reported Outcomes Research (CPROR), Institute of Applied Health Research at the University of Birmingham, looked at international examples of the use of electronic patient-reported outcome (ePRO) systems to triage clinical care.

    ePROs allow patients to fill out questionnaires at home or location of their choice, with the results sent back to the clinician in near real-time to use in clinical decision-making. Studies of various groups of patients, including those with epilepsy, sleep apnoea, type 1 diabetes, cancer, rheumatoid arthritis and HIV, were included in the review. In Denmark Ambuflex, a generic ePRO system, has been used in over 40,000 patients across a range of chronic conditions and has led to substantial reductions in outpatient appointments. In epilepsy clinics, the system led to reductions of up to 48% in in-person outpatient appointments.

    Lead author Dr Lee Aiyegbusi, Associate Professor and Deputy Director at CPROR, said: “The use of PROs is well established in research settings to evaluate the effectiveness, cost-effectiveness and tolerability of interventions from a patient perspective. Clinicians are now interested in using patient-level symptom reporting for the clinical management of individual patients in routine practice.”

    The review provides evidence to support the implementation of ePRO systems for outpatient care, including significant reductions in outpatient appointments without compromising patient outcomes or satisfaction with care.

    Dr Aiyegbusi said: “ePROs for outpatient care could facilitate the tailoring of care to patient needs. Stable patients can be monitored remotely using ePROs, thereby avoiding unnecessary check-ups in outpatient clinics and associated costs, such as travel and time off work, without lowering the quality of treatment. This efficient use of scarce healthcare resources could free up outpatient clinics for patients with high symptom burden or concerning symptoms, so they can be seen more quickly.”

    The authors say it is important to acknowledge that a proportion of patients, especially the elderly, may prefer face-to-face or telephone outpatient consultations regardless of their health status and may be concerned about or averse to the use of ePROs as a triaging tool.

    They also say the findings demonstrate why it is crucial that the use of ePROs for outpatient care is carefully considered, planned and implemented to ensure that people from underserved populations are not further disadvantaged.

    They concluded: “The use of ePROs in outpatient care could potentially allow a more responsive healthcare system, reduce demand for clinic appointments, reduce time to care with associated improved outcomes, and enhance cost-effectiveness of healthcare delivery – all of which are beneficial to patients, their families and society.”

    [ad_2]

    SAGE Publications UK

    Source link

  • GE’s Larry Culp Has a Message for Investors

    GE’s Larry Culp Has a Message for Investors

    [ad_1]

    This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

    https://www.barrons.com/articles/ge-larry-culp-investors-annual-letter-83f4e20b

    • Order Reprints
    • Print Article

    [ad_2]

    Source link

  • Robinhood accidentally sold short on a meme stock and lost $57 million

    Robinhood accidentally sold short on a meme stock and lost $57 million

    [ad_1]

    Robinhood Markets Inc. accidentally sold short on a small stock as it went on a meme-like ride in December, costing the trading app more than the stock’s current market capitalization, executives disclosed Wednesday.

    Cosmos Health Inc.
    COSM,
    +0.80%
    shares nearly tripled and experienced record trading volume more than seven times any previous day on Dec. 16, as online traders looking for heavily shorted companies accused exchanges of not allowing them to sell their shares into the updraft. Robinhood
    HOOD,
    -0.76%
    executives admitted Wednesday that their trading app actually became part of the frenzy, and ended up down $57 million because of it.

    In an earnings call, Robinhood Chief Executive Vlad Tenev noted a “processing error on a corporate action” that was “really disappointing,” leaving Chief Financial Officer Jason Warnick to spell it out.

    “A processing error caused us to sell shares short into the market, and although it was detected quickly, it resulted in a loss of $57 million as we bought back these shares against a rising stock price,” Warnick said.

    When Cosmos Health effected a 1-for-25 reverse stock split that Friday morning in December, just hours after announcing its intentions, trading portals did not appear prepared. As MarketWatch reported on the day, TD Ameritrade publicly told Twitter users that the company had not received the newly issued shares to dole out to their clients as the stock spiked. A Charles Schwab Corp.
    SCHW,
    -0.71%
    spokesperson emailed MarketWatch the next week to say that the distributions were all taken care of as of the end of the next business day, a Monday.

    The stock gains didn’t last through that Monday, though — after reaching as high as $23.84 on the day that Robinhood was apparently buying, they lost it all in after-hours trading and headed even lower after Cosmos Health announced an equity offering.

    Shares closed Wednesday at $5.04, which gives Cosmos Health a market cap of about $53 million, according to FactSet — less than Robinhood executives said they lost on the Dec. 16 trades.

    Robinhood shares were up in after-hours trading Wednesday after the trading app reported a fourth-quarter miss, but said the company would seek to buy back shares sold to disgraced cryptocurrency-exchange founder Sam Bankman-Fried and executives would forego $500 million in stock compensation. Robinhood stock has declined 21.8% in the past 12 months, as the S&P 500 index
    SPX,
    -1.11%
    has dropped 8.9%.

    [ad_2]

    Source link

  • Training Individuals to Work in their Communities to Reduce Health Disparities

    Training Individuals to Work in their Communities to Reduce Health Disparities

    [ad_1]

    Newswise — Community health workers were trusted messengers, disseminating health information in underserved communities during the COVID-19 pandemic, and playing a vital role in reducing health disparities. 

    This form of outreach is the basis of a newly launched academic-community partnership, led by the Herbert Wertheim School of Public Health and Human Longevity Science at University of California San Diego and is funded by a $3-million Health Resources and Services Administration grant, that aims to train 200 individuals from refugee, immigrant, and Native American populations living in San Diego County to become community health workers on key health topics disproportionately affecting their communities.

    “COVID-19 highlighted the need for individuals with culturally and linguistically competent skills to be engaged as community health workers within their own neighborhoods. At the urging of our community collaborators to design a certified training program, I felt responsibility to take that role and address health disparity that is negatively impacting these communities,” said Wael Al-Delaimy, M.D., Ph.D., professor at the Herbert Wertheim School of Public Health and Human Longevity Science, who is bilingual and an immigrant from the Middle East.

    Nationally, San Diego is the second largest hub for immigrants from the Middle East and Somalia, two populations targeted by this program.

    Al-Deliamy is the director of the newly funded initiative titled Community Health Workers for Advancing Public Health within Immigrant/Refugee and Native American Communities Program (CHWAP), which is a collaboration with the UC San Diego Division of Extended Studies, UC San Diego Altman Clinical and Translational Research Institute (ACTRI) Center for Community Health, Somali Family Service of San Diego, and more than 14 community organization partners.

    The program will provide all-expenses paid training that will be held in combination of community settings, at the UC San Diego campus, and online.

    Somali Family Service will recruit trainees from underserved communities and will provide additional services including transportation, childcare, mentorship and career services such as resume writing and cover letter development workshops. It will also assist participants to find living wage jobs.

    “It is important for community members to access trusted messengers equipped with the capacity to holistically relate and respond to their needs and concerns while providing valuable and impactful services and solutions,” said Ahmed Sahid, president and CEO of Somali Family Service of San Diego.

    “The Community Health Workers for Advancing Public Health within Immigrant/Refugee and Native American Communities Program significantly bolsters our community health workers’ efforts by ensuring they receive the training, tools and support necessary to uplift underserved and vulnerable communities.”

    Community health workers are not medical or public health professionals. They are individuals who bridge culture, language and life experiences with public health, health care and the needs of the community in which they live.

    The Herbert Wertheim School of Public Health competed and was selected to become part of a national network to develop capacity in training 13,000 community health workers through a $225 million HRSA program under the directive of the White House.

    UC San Diego Division of Extended Studies will oversee the academic components of CHWAP, providing access to world-class training in health support, soft skills development, and leadership and self-care.  

    “We hope to train as many as 200 new community health workers over the next three years and are honored to work with the Herbert Wertheim School of Public Health and Human Longevity Science and our community partners to ensure a talented and diverse public health workforce and reduce healthcare disparities in our region,” said Laura B. Fandino, J.D., Ph.D., assistant dean of academic affairs, Division of Extended Studies. 

    Among the community organizations helping to recruit community health workers is the San Diego Refugee Communities Coalition, a collective of ethnic-community based organizations in San Diego County with a history of serving thousands of underserved refugee families and residents. The ACTRI Center for Community Health Refugee Health Unit serves as the backbone organization for the coalition.

    CHWAP will provide an opportunity for expanded workforce development within refugee and underserved communities to improve access to health resources in a way that was unavailable prior to the COVID-19 pandemic, said Blanca Meléndrez, executive director of the ACTRI Center for Community Health and co-director of CHWAP.

    “Community health workers can provide culturally competent, locally relevant services to individuals in their primary language which makes community members more comfortable and open to discussing sensitive topics,” said Amina Sheik-Mohamed, M.P.H., ACTRI Center for Community Health Refugee Health Unit director.

    Chag Lowry, who is of Yurok, Maidu, and Achumawi Native ancestry from California, will be coordinating the program’s outreach and recruitment effort to Native Americans. 

    “Our Native American community suffered health inequity for decades and was hit hard by the COVID-19 pandemic. This is a welcome effort to build capacity in an effort to address the health equity gap,” said Lowry, administrative director of the California American Indian Tobacco Initiative Evaluation based at the Herbert Wertheim School of Public Health.

    CHWAP will coordinate job placements and development of an apprenticeship program with hospitals, clinics and regional partners including the San Diego Workforce Partnership, said Eric Hekler, Ph.D., CHWAP co-director and associate dean for community partnerships at the Herbert Wertheim School of Public Health.

    In addition, CHWAP is collaborating with the California Consortium for Urban Indian Health, the County of San Diego, Health Center Partners of Southern California, the Hospital Association of San Diego and Imperial Counties, and Family Health Centers of San Diego.

    “Part of the mission of the Herbert Wertheim School of Public Health and Human Longevity Science is to collaborate with diverse partners to develop community-led health solutions,” said Hekler.  

    “The Community Health Workers for Advancing Public Health within Immigrant/Refugee and Native American Communities Program helps us cultivate our capacity to serve our local communities by training and supporting job placement of people within their neighborhoods as well as influence health inequities.”

    Information about the program and how to enroll is available on the CHWAP website. 

    This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $3 million with no other non-governmental sources. The contents are those of the author and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the United States government. For more information, please visit HRSA.gov

    [ad_2]

    University of California San Diego

    Source link

  • Mayo Clinic opens patient information office in India

    Mayo Clinic opens patient information office in India

    [ad_1]

    Newswise — MUMBAI, India — Mayo Clinic has opened a patient information office in Mumbai to assist patients who wish to make appointments at Mayo Clinic locations worldwide.

    The office staff, fluent in Hindi and English, will help patients, their families and physicians who refer patients to make appointments at Mayo Clinic in Rochester, Minnesota; Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Mayo Clinic Healthcare in London.

    “We are pleased to add an office in Mumbai to our patient appointment services,” says Mohamad Bydon, M.D., a Mayo Clinic neurosurgeon and executive medical director of academic affairs and the Europe, Middle East, India and Africa regions. “Mayo Clinic seeks to serve as a resource for patients and health care providers around the world. Our international patient information offices help us provide patients with a seamless experience when seeking care at Mayo Clinic.”

    The Mumbai office staff will assist with travel, lodging, billing and insurance arrangements; provide general orientation to Mayo Clinic; facilitate Mayo review of medical records; and coordinate future appointments. The office does not provide medical attention.

    Learn more at https://www.mayoclinic.org/departments-centers/international/locations/india-representative.

    Mayo Clinic also has patient information offices in Canada, Colombia, the Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Panama and Peru.

    Mayo Clinic accepts appointment requests directly from patients and patient referrals from physicians. Interpreters are available at no cost to assist with communication between health care providers and patients whose primary language is not English.

    Mayo Clinic is ranked the best hospital in the world by Newsweek and the No. 1 hospital in the U.S. by U.S. News & World Report. Mayo Clinic serves roughly 1.4 million people from 139 countries every year.

    About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

    [ad_2]

    Mayo Clinic

    Source link

  • Cardiovascular Specialist Needed for Your Cancer Treatment?

    Cardiovascular Specialist Needed for Your Cancer Treatment?

    [ad_1]

    Newswise — As cancer treatments have evolved over the years, cancer survival has improved, but the new forms of chemotherapy and radiation therapy can cause lasting damage to the heart. 

    Accomplished physician and pioneer in cardio-oncology research and education, L. Steven Zukerman, M.D., FACC, medical director of the Cardio-Oncology Program at Hackensack Meridian Jersey Shore University Medical Center in Neptune, NJ, is addressing this concern.

    The program is designed to minimize the impact of cancer treatments on patients’ hearts and provide continuing cardiac care to cancer survivors and provides patients access to experts in cardiology and oncology and advanced imaging services.  “Our multidisciplinary program provides patients with seamless and expert care as we monitor and protect their hearts before, during, and after cancer treatment,” says Dr. Zukerman.

    A range of patients can be treated and monitored through the cardio-oncology program.  They include patients who will begin chemotherapy or radiation therapy and have risk factors for heart disease or are being treated for heart disease.  Patients who are experiencing cardiac symptoms or complications during cancer therapy are also candidates for the program, this includes high-blood pressure, congestive heart failure, and heart arrhythmias.  Screening for radiation-induced coronary artery disease, valvular heart disease, and pericardial disease is also provided.

    Cancer patients currently receiving treatment receive regular heart function assessments.  Patients who are cancer survivors, including those who received cancer treatment as children, are monitored for heart disease risk and if needed, receive continuing medical care to maintain heart function.

    Dr. Zukerman is board-certified in internal medicine and cardiovascular disease and completed his internal medicine internship at McGaw Medical Center of Northwestern University.  He completed his internal medicine residency, cardiology fellowship, and his clinical cardiac electrophysiology training at the Medical College of Pennsylvania.

    The program, located in the cancer center on the academic medical center’s campus in the HOPE Tower, was funded in part through a gift of $500,000 from one of Dr. Zukerman’s grateful patients, given to at the time, the Jersey Shore University Medical Center Foundation.

    Interviews are available with Dr. Zukerman.  He can provide information about how cancer treatment impacts the heart, the importance of cardiac care before, during and after cancer treatment as well as the modalities of this care and heart monitoring.  Especially relevant during February, National Heart Month.     

    [ad_2]

    Hackensack Meridian Health

    Source link